The addition of the first-in-class direct lytic agent exebacase (lysin CF-301) to standard-of-care (SOC) antibiotics demonstrated efficacy against Staphylococcus aureus bacteraemia (SAB), particularly difficult-to-treat methicillin-resistant SA (MRSA), compared with SOC antibiotics alone, according to the results of a phase II trial presented at ECCMID 2019.
The novel human monoclonal antibody suvratoxumab yielded a trend toward reducing the incidence of Staphylococcus aureus pneumonia (SAP) in high-risk, mechanically-ventilated intensive care unit (MV ICU) patients with an acceptable safety profile, according to data from the phase II SAATELLITE* trial presented at ECCMID 2019.
The selective cap-dependent endonuclease inhibitor baloxavir marboxil (hereafter baloxavir) effectively improves influenza symptoms in adolescent patients and those at high risk for influenza complications, according to two subanalyses of the CAPSTONE studies presented at ECCMID 2019.
The novel pleuromutilin antibiotic lefamulin - now in an oral therapy form - has demonstrated a favourable safety and tolerability profile for community-acquired bacterial pneumonia (CABP) in the LEAP* 2 study, the same result seen for intravenous (IV) lefemulin in the original LEAP 1 study.
Many patients prescribed antibiotics for suspected urinary tract infection (UTI) in the emergency department (ED) may not actually require them, according to a single-centre study from the UK presented at ECCMID 2019.
The combination of the antipseudomonal cephalosporin, ceftolozane, and an extended-spectrum β-lactamase inhibitor, tazobactam (ceftolozane/tazobactam), is noninferior to meropenem in the treatment of adults with ventilated nosocomial pneumonia (VNP), phase 3 data from the ASPECT-NP* trial have shown.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.